Ultimovacs Receives Notice of Allowance on US Patent on Vaccine-Checkpoint Inhibitor Combinations

Ultimovacs Receives Notice of Allowance on US Patent on Vaccine-Checkpoint Inhibitor Combinations

22 Apr 2022 08:00 CEST

* Extends protection for UV1 vaccine-checkpoint inhibitor combinations until
at least 2037
* Covers UV1 with CTLA-4, PD-1 or PD-L1 checkpoint inhibitors

Oslo, 22 April 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage
leader in immune stimulatory vaccines for cancer, received a Notice of Allowance
from the United States Patent and Trademarks Office (USPTO) concerning its US
patent application 16/306,352 on the use of vaccine-checkpoint inhibitor
combinations to treat cancer. Subject to grant formalities, it is expected that
a patent will issue with a patent term up to at least June 2037. Ultimovacs has
similar patent applications pending in other territories worldwide, including
Europe, Japan, Canada and Australia.

The scope of the patent, when issued, will cover cancer treatments that include
the UV1 peptide vaccine in combination with an anti-CTLA-4, anti-PD-1 or anti-
PD-L1 antibody checkpoint inhibitor. The primary patents of many of the current
CTLA-4 and PD-1/PD-L1 checkpoint inhibitors face expiry over the course of the
next several years.

"We are pleased that Ultimovacs' innovative contributions to combination
immunotherapies in cancer have been validated by the USPTO," said Carlos de
Sousa, Chief Executive Officer of Ultimovacs. "The company's universal cancer
vaccine UV1 is being assessed in combination with checkpoint inhibitors in five
phase 2 trials for various cancers. The allowed claims will cover such
combination treatments across these and other cancer indications and will extend
proprietary use of the vaccine in combination with these checkpoint inhibitors
until at least 2037."

==ENDS==

About Ultimovacs
Ultimovacs is developing immune-stimulatory vaccines to treat a broad range of
cancers. Ultimovacs' lead universal cancer vaccine candidate UV1 targets human
telomerase (hTERT), present in 85-90% of cancers in all stages of tumor growth.
By directing the immune system to hTERT antigens, UV1 drives CD4 helper T cells
to the tumor to activate an immune system cascade and increase anti-tumor
responses. With a broad Phase II program, Ultimovacs aims to clinically
demonstrate UV1's impact in multiple cancer types in combination with other
immunotherapies. Ultimovacs' second technology approach, based on the
proprietary Tetanus-Epitope-Targeting (TET) platform, combines tumor-specific
peptides and adjuvant in the same molecule and entered Phase I studies in 2021.

For further information, please see www.ultimovacs.com or contact:

Carlos de Sousa, CEO
Email: [email protected]
Phone: +47 908 92507

Anne Worsøe, Head of IR & Communication
Email: [email protected]
Phone: +47 906 86815

Mary-Ann Chang, LifeSci Advisors
Email: [email protected]
Phone: +44 7483 284 853

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to Section 5-12 in the Norwegian Securities Trading Act.

This stock exchange announcement was published by Joachim Midttun, Finance
Manager at Ultimovacs ASA, on 22 April, 2022 at 8:00 CET

More information:
Access the news on Oslo Bors NewsWeb site

Source

Ultimovacs ASA

Provider

Oslo Børs Newspoint